These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25148431)

  • 1. Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer.
    Costa-Pinheiro P; Patel HR; Henrique R; Jerónimo C
    Expert Rev Anticancer Ther; 2014 Nov; 14(11):1349-58. PubMed ID: 25148431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of proteomics in prostate cancer research: biomarker discovery and validation.
    Pin E; Fredolini C; Petricoin EF
    Clin Biochem; 2013 Apr; 46(6):524-38. PubMed ID: 23266295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular diagnosis of prostate cancer: are we up to age?
    Bhavsar T; McCue P; Birbe R
    Semin Oncol; 2013 Jun; 40(3):259-75. PubMed ID: 23806492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [High-risk clinically localised prostate cancer].
    Rozet F; Cornu JN; Cussenot O; Fromont G; Hennequin C
    Bull Cancer; 2010 Dec; 97(12):1517-36. PubMed ID: 21220228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New biomarkers in prostate cancer].
    Provenzano M
    Praxis (Bern 1994); 2012 Jan; 101(2):115-21. PubMed ID: 22252593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
    Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene.
    Taneja SS; Morton R; Barnette G; Sieber P; Hancock ML; Steiner M
    J Clin Oncol; 2013 Feb; 31(5):523-9. PubMed ID: 23295793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer screening using risk stratification based on a multi-state model of genetic variants.
    Yen AM; Auvinen A; Schleutker J; Wu YY; Fann JC; Tammela T; Chen SL; Chiu SY; Chen HH
    Prostate; 2015 Jun; 75(8):825-35. PubMed ID: 25683204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of developing prostate cancer in the future: overview of prognostic biomarkers.
    Fleshner NE; Lawrentschuk N
    Urology; 2009 May; 73(5 Suppl):S21-7. PubMed ID: 19375623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can molecular markers stratify the diagnostic value of high-grade prostatic intraepithelial neoplasia?
    Hailemariam S; Vosbeck J; Cathomas G; Zlobec I; Mattarelli G; Eichenberger T; Zellweger T; Bachmann A; Gasser TC; Bubendorf L
    Hum Pathol; 2011 May; 42(5):702-9. PubMed ID: 21237492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood biomarkers for prostate cancer detection and prognosis.
    Shariat SF; Karam JA; Roehrborn CG
    Future Oncol; 2007 Aug; 3(4):449-61. PubMed ID: 17661720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New circulating biomarkers for prostate cancer.
    Bensalah K; Lotan Y; Karam JA; Shariat SF
    Prostate Cancer Prostatic Dis; 2008; 11(2):112-20. PubMed ID: 17998918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.
    Ferro M; Bruzzese D; Perdonà S; Mazzarella C; Marino A; Sorrentino A; Di Carlo A; Autorino R; Di Lorenzo G; Buonerba C; Altieri V; Mariano A; Macchia V; Terracciano D
    Clin Chim Acta; 2012 Aug; 413(15-16):1274-8. PubMed ID: 22542564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular markers to guide primary radical treatment selection in localized prostate cancer.
    Gnanapragasam VJ
    Expert Rev Mol Diagn; 2014 Sep; 14(7):871-81. PubMed ID: 24994559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathways to personalized medicine for breast and prostate cancers: emerging diagnostic methods and prognostic biomarkers.
    Watson AP; Egland KA
    S D Med; 2010 Jul; 63(7):247-53. PubMed ID: 20666024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical applications of molecular biomarkers in prostate cancer detection.
    Dumache R; Miclea F; Bumblăcilă B; Puiu M
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(2):470-5. PubMed ID: 20700989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches.
    Miyake H; Fujisawa M
    Int J Urol; 2013 Mar; 20(3):301-11. PubMed ID: 23020893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.
    Fredolini C; Liotta LA; Petricoin EF
    Crit Rev Clin Lab Sci; 2010; 47(3):125-38. PubMed ID: 20858067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and predictive biomarkers in prostate cancer.
    Kontos CK; Adamopoulos PG; Scorilas A
    Expert Rev Mol Diagn; 2015; 15(12):1567-76. PubMed ID: 26548550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
    Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
    Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.